CL2023002004A1 - Terapia combinada que comprende un inhibidor de la vía jak y un inhibidor de roca. - Google Patents
Terapia combinada que comprende un inhibidor de la vía jak y un inhibidor de roca.Info
- Publication number
- CL2023002004A1 CL2023002004A1 CL2023002004A CL2023002004A CL2023002004A1 CL 2023002004 A1 CL2023002004 A1 CL 2023002004A1 CL 2023002004 A CL2023002004 A CL 2023002004A CL 2023002004 A CL2023002004 A CL 2023002004A CL 2023002004 A1 CL2023002004 A1 CL 2023002004A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitor
- combination therapy
- rock
- jak pathway
- rock inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000011435 rock Substances 0.000 title abstract 2
- 230000037361 pathway Effects 0.000 title 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 2
- 208000024908 graft versus host disease Diseases 0.000 abstract 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 206010062237 Renal impairment Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005977 kidney dysfunction Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135969P | 2021-01-11 | 2021-01-11 | |
| US202163253384P | 2021-10-07 | 2021-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002004A1 true CL2023002004A1 (es) | 2023-12-15 |
Family
ID=80119468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002004A CL2023002004A1 (es) | 2021-01-11 | 2023-07-10 | Terapia combinada que comprende un inhibidor de la vía jak y un inhibidor de roca. |
| CL2024000773A CL2024000773A1 (es) | 2021-01-11 | 2024-03-14 | Terapia combinada que comprende el inhibidor de la vía jak y el inhibidor de rock. (div 202302004) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000773A CL2024000773A1 (es) | 2021-01-11 | 2024-03-14 | Terapia combinada que comprende el inhibidor de la vía jak y el inhibidor de rock. (div 202302004) |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11918581B2 (https=) |
| EP (1) | EP4274578A1 (https=) |
| JP (1) | JP2024503021A (https=) |
| KR (1) | KR20230157307A (https=) |
| AU (1) | AU2022206313A1 (https=) |
| CA (1) | CA3207859A1 (https=) |
| CL (2) | CL2023002004A1 (https=) |
| IL (1) | IL304320A (https=) |
| MX (1) | MX2023008141A (https=) |
| TW (1) | TW202237083A (https=) |
| WO (1) | WO2022150676A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| WO2024153147A1 (zh) * | 2023-01-18 | 2024-07-25 | 北京普祺医药科技股份有限公司 | 一种氮杂环烷烃化合物、药物组合物及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005723A1 (fr) | 1988-11-24 | 1990-05-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine |
| PT868186E (pt) | 1995-12-21 | 2005-05-31 | Alcon Lab Inc | Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular |
| NZ513800A (en) | 1996-08-12 | 2001-09-28 | Welfide Corp | Treatment of diseases using Rho kinase inhibitors |
| DE69922494T2 (de) | 1998-02-04 | 2005-05-25 | Banyu Pharmaceutical Co., Ltd. | Zyklische n-acylamin-derivate |
| JP4212149B2 (ja) | 1998-06-11 | 2009-01-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 医薬 |
| AU5198199A (en) | 1998-08-17 | 2000-03-06 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| ATE273695T1 (de) | 2000-06-28 | 2004-09-15 | Smithkline Beecham Plc | Nassvermahlung |
| US20030125344A1 (en) | 2001-03-23 | 2003-07-03 | Bayer Corporation | Rho-kinase inhibitors |
| MXPA03008659A (es) | 2001-03-23 | 2005-04-08 | Bayer Ag | Inhibidores de rho-cinasa. |
| JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| WO2005080394A1 (en) | 2004-02-24 | 2005-09-01 | Bioaxone Therapeutique Inc. | 4-substituted piperidine derivatives |
| TWI367098B (en) | 2004-12-23 | 2012-07-01 | Kowa Co | Treating agent for glaucoma |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| EP3070090B1 (en) | 2007-06-13 | 2018-12-12 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| JP5775070B2 (ja) | 2009-05-22 | 2015-09-09 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体 |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| PT3354652T (pt) | 2010-03-10 | 2020-07-20 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| AU2013274030B2 (en) | 2012-06-15 | 2016-07-07 | Sun Pharmaceutical Industries, Inc. | Deuterated derivatives of ruxolitinib |
| CA2880083A1 (en) | 2012-08-17 | 2014-02-20 | Concert Pharmaceuticals, Inc. | Deuterated baricitinib |
| CN113620933A (zh) | 2012-10-05 | 2021-11-09 | 卡德门企业有限公司 | Rho激酶抑制剂 |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| WO2014138168A1 (en) | 2013-03-06 | 2014-09-12 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
| SMT201900223T1 (it) | 2013-05-17 | 2019-07-11 | Incyte Corp | Sale di bipirazolo come inibitore di jak |
| SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| MA55201A (fr) * | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
-
2022
- 2022-01-10 EP EP22702088.0A patent/EP4274578A1/en active Pending
- 2022-01-10 CA CA3207859A patent/CA3207859A1/en active Pending
- 2022-01-10 TW TW111100922A patent/TW202237083A/zh unknown
- 2022-01-10 KR KR1020237027442A patent/KR20230157307A/ko active Pending
- 2022-01-10 AU AU2022206313A patent/AU2022206313A1/en active Pending
- 2022-01-10 JP JP2023541734A patent/JP2024503021A/ja active Pending
- 2022-01-10 MX MX2023008141A patent/MX2023008141A/es unknown
- 2022-01-10 US US17/571,844 patent/US11918581B2/en active Active
- 2022-01-10 WO PCT/US2022/011756 patent/WO2022150676A1/en not_active Ceased
-
2023
- 2023-07-09 IL IL304320A patent/IL304320A/en unknown
- 2023-07-10 CL CL2023002004A patent/CL2023002004A1/es unknown
-
2024
- 2024-02-01 US US18/430,205 patent/US20240293411A1/en active Pending
- 2024-03-14 CL CL2024000773A patent/CL2024000773A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024503021A (ja) | 2024-01-24 |
| US20220226327A1 (en) | 2022-07-21 |
| TW202237083A (zh) | 2022-10-01 |
| IL304320A (en) | 2023-09-01 |
| MX2023008141A (es) | 2023-10-20 |
| CL2024000773A1 (es) | 2024-09-23 |
| EP4274578A1 (en) | 2023-11-15 |
| AU2022206313A1 (en) | 2023-08-31 |
| US20240293411A1 (en) | 2024-09-05 |
| KR20230157307A (ko) | 2023-11-16 |
| CA3207859A1 (en) | 2022-07-14 |
| WO2022150676A1 (en) | 2022-07-14 |
| US11918581B2 (en) | 2024-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002004A1 (es) | Terapia combinada que comprende un inhibidor de la vía jak y un inhibidor de roca. | |
| MX2020003959A (es) | Metodos terapeuticos relacionados con los inhibidores de hsp90. | |
| MX2020004948A (es) | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. | |
| DOP2022000016A (es) | Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores del punto de control inmune para el tratamiento del cáncer | |
| MX2020009773A (es) | Terapia de combinacion. | |
| CL2017002904A1 (es) | Métodos y kits para tratar la depresión | |
| BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
| EP4620525A3 (en) | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | |
| AR099707A1 (es) | Composiciones y métodos para tratar trastornos renales | |
| CL2021001814A1 (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp. | |
| PE20211196A1 (es) | Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| CL2020000271A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina. | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| MX2020004914A (es) | Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| WO2016161055A3 (en) | Methods of treating cancers, autoimmune disorders, and other conditions associated with chronic inflammation | |
| CL2022001006A1 (es) | Inhibidores de tim-3 y sus usos | |
| BR112021020525A2 (pt) | Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação | |
| CL2021000585A1 (es) | Métodos para tratar la pancreatitis | |
| JOP20250150A1 (ar) | علاجات السرطان باستخدام مثبطات prmt5 التعاونية مع mta | |
| AR122933A1 (es) | Métodos para tratar la enfermedad cardiovascular | |
| MX2025008270A (es) | Uso prolongado de docetaxel en el tratamiento del cáncer. | |
| MX2021001764A (es) | Terapia de combinacion. | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. |